The Sudeep Pharma IPO has become one of the most talked-about offerings of the month. The buzz started building from the first bidding day itself, and by the time the issue neared its close, the subscription numbers were already telling a clear story—investor interest was strong and consistent.
Market Performance: How the IPO Buildup Played Out
The IPO opened on November 21 and is scheduled to close on November 25.
Right from the first hour, the flow of bids showed that the offering was drawing interest across investor categories.
Here’s how the subscription trend developed:
- Day 1 subscription: 1.42x
- Day 2 subscription: 5.09x
- By Day 3 (so far): 8.79x
- BSE data at 11:03 IST:
- Shares offered: 1,05,64,926
- Shares bid: 8,86,65,875
The allocation split followed the standard structure:
- QIBs: Up to 50%
- NIIs: Minimum 15%
- Retail: At least 35%
Category-wise subscription on Day 2 added more clarity to the demand:
- Retail: 6.75x
- NII: 23.20x
- QIB: 16%
The numbers alone underline that the Sudeep Pharma IPO subscription status stayed strong across all segments.
Main News: Price Band, Dates, and What the Company Offers
The Sudeep Pharma IPO price band has been set at ₹563–₹593 per share.
The offering includes:
- Fresh issue: ₹95 crore
- Offer for sale (OFS): ~1.35 crore equity shares
- Total value: ₹800 crore from promoters
The timeline for the IPO is tight and structured:
- IPO open date: November 21
- IPO close date: November 25
- Allotment date: November 26
- Refunds: November 27
- Demat credit: November 27
- Listing date: November 28
- Exchanges: BSE and NSE
Every step has been aligned with a smooth listing process, making dates like the Sudeep Pharma IPO allotment date and the Sudeep Pharma IPO listing date important search points for investors.
Company Details: What Sudeep Pharma Does
Sudeep Pharma is based in Gujarat and operates as one of the key manufacturers of food-grade iron phosphate. Its ingredients are used in:
- Infant nutrition
- Clinical nutrition
- Food and beverages
The company has built its presence around mineral-based products such as:
- Calcium
- Iron
- Magnesium
- Zinc
- Potassium
- Sodium
All of this production happens across six manufacturing plants, together offering a total capacity of 50,000 MT.
These details make Sudeep Pharma IPO a major point of curiosity for investors trying to understand the business model behind the offering.
Sudeep Pharma’s Expansion and Operations
Within the reference content, one notable detail stands out—Sudeep Pharma has a wholly owned subsidiary named SAMPL.
The purpose of this subsidiary includes:
- Using its mineral expertise to enter advanced materials
- Setting up a plant for PCAM production
- Working on battery-grade iron phosphate
- Aligning with sectors like electric vehicles and energy storage
The company also emphasises moving deeper into regulated markets, such as:
- The United States
- Europe
Supported through:
- USFDA-approved facilities
- Focus on exports
- Direct market access through warehousing and sales
These operational elements add depth to the Sudeep Pharma IPO review conversations across investor groups.
Financial Utilisation Plan
The IPO’s fresh issue proceeds, totalling ₹75.81 crore, will be used for:
- Machinery acquisition for the Nandesari Facility 1 in Gujarat
- General corporate purposes
This financial breakdown is crucial for anyone exploring the Sudeep Pharma IPO details before taking a deeper look into the company’s structure.
Summary: A Data-Led Look at Sudeep Pharma IPO
The Sudeep Pharma IPO has drawn strong interest, as shown through its subscription numbers—1.42x on Day 1, 5.09x on Day 2, and 8.79x so far on Day 3.
Its price band of ₹563-₹593, combined with a structured timeline ending with the listing on November 28, has kept the IPO in sharp focus across the market.
With six manufacturing units, 50,000 MT capacity, a significant presence in mineral-based ingredients, and expansion into advanced materials, the company’s operational depth adds context to the interest around the IPO.
Easy & quick
Leave A Comment?